ZA202300862B - Flt3 ligand fusion proteins and methods of use - Google Patents

Flt3 ligand fusion proteins and methods of use

Info

Publication number
ZA202300862B
ZA202300862B ZA2023/00862A ZA202300862A ZA202300862B ZA 202300862 B ZA202300862 B ZA 202300862B ZA 2023/00862 A ZA2023/00862 A ZA 2023/00862A ZA 202300862 A ZA202300862 A ZA 202300862A ZA 202300862 B ZA202300862 B ZA 202300862B
Authority
ZA
South Africa
Prior art keywords
methods
fusion proteins
flt3 ligand
ligand fusion
effectorless
Prior art date
Application number
ZA2023/00862A
Other languages
English (en)
Inventor
Liu Yichin
Carine Moussion Christine
William Bainbridge Travis
Hosseini Iraj
Alan Lazar Gregory
Cohen Sivan
Charles Kemball Christopher
M Schartner Jill
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA202300862B publication Critical patent/ZA202300862B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2023/00862A 2020-08-07 2023-01-19 Flt3 ligand fusion proteins and methods of use ZA202300862B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062713P 2020-08-07 2020-08-07
PCT/US2021/044586 WO2022031876A1 (en) 2020-08-07 2021-08-05 Flt3 ligand fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
ZA202300862B true ZA202300862B (en) 2025-05-28

Family

ID=77519822

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/00862A ZA202300862B (en) 2020-08-07 2023-01-19 Flt3 ligand fusion proteins and methods of use

Country Status (18)

Country Link
US (2) US11542308B2 (https=)
EP (1) EP4192854A1 (https=)
JP (1) JP7847578B2 (https=)
KR (1) KR20230042596A (https=)
CN (1) CN116234830A (https=)
AR (1) AR123158A1 (https=)
AU (1) AU2021322239A1 (https=)
BR (1) BR112023002123A2 (https=)
CA (1) CA3188426A1 (https=)
CL (1) CL2023000381A1 (https=)
CO (1) CO2023001488A2 (https=)
CR (1) CR20230119A (https=)
IL (1) IL300260A (https=)
MX (2) MX2023001441A (https=)
PE (1) PE20230983A1 (https=)
TW (1) TW202221016A (https=)
WO (1) WO2022031876A1 (https=)
ZA (1) ZA202300862B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002123A2 (pt) * 2020-08-07 2023-03-07 Genentech Inc Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
EP4532728A2 (en) * 2022-06-03 2025-04-09 The University of Chicago Antigen tolerance induction through use of flt3l variants

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US7294331B2 (en) 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2003040311A2 (en) 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA04009394A (es) * 2002-03-26 2005-01-25 Inmunex Corp Metodos para utilizar ligando flt3 en procedimientos de inmunizacion.
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050232931A1 (en) 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CA2595676A1 (en) 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
GB201107170D0 (en) 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US11369663B2 (en) * 2016-06-07 2022-06-28 Washington University Detection of CD5 and methods and compositions for modulating CD5
CN109757103B (zh) * 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
US11246908B2 (en) 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
CA3093696A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
US10780121B2 (en) * 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2020069382A1 (en) 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
US20220177550A1 (en) * 2019-03-28 2022-06-09 Orionis Biosciences, Inc. Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
WO2020263830A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
PE20231104A1 (es) * 2020-07-21 2023-07-19 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
BR112023002123A2 (pt) * 2020-08-07 2023-03-07 Genentech Inc Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo

Also Published As

Publication number Publication date
JP7847578B2 (ja) 2026-04-17
WO2022031876A1 (en) 2022-02-10
CR20230119A (es) 2023-05-16
CL2023000381A1 (es) 2023-07-28
AR123158A1 (es) 2022-11-02
JP2023536655A (ja) 2023-08-28
BR112023002123A2 (pt) 2023-03-07
IL300260A (en) 2023-03-01
PE20230983A1 (es) 2023-06-21
US20220289803A1 (en) 2022-09-15
US20230279067A1 (en) 2023-09-07
MX2023001440A (es) 2023-03-06
MX2023001441A (es) 2023-03-06
KR20230042596A (ko) 2023-03-28
EP4192854A1 (en) 2023-06-14
CN116234830A (zh) 2023-06-06
AU2021322239A1 (en) 2023-02-23
CA3188426A1 (en) 2022-02-10
US11542308B2 (en) 2023-01-03
TW202221016A (zh) 2022-06-01
CO2023001488A2 (es) 2023-02-16

Similar Documents

Publication Publication Date Title
ZA202300862B (en) Flt3 ligand fusion proteins and methods of use
MY205418A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2020247843A8 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
ZA202300423B (en) Fusion constructs and methods of using thereof
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
MX2020010912A (es) Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas.
EP4659757A3 (en) Multi-chain chimeric polypeptides and uses thereof
SA521421825B1 (ar) (glp1) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (gdf15) وعامل تمايز النمو 15 واستخدامه
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
MX2020010910A (es) Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
TW200732350A (en) Methods for generating monovalent IgG
CL2018000358A1 (es) Proteínas de fusión de gitrl y usos de las mismas
PH12017502025A1 (en) Fusion proteins
MY202559A (en) Anti-ctla-4 antibody and use thereof
SG11202006259SA (en) Il-22 fc fusion proteins and methods of use
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
MX2015009502A (es) Anticuerpos que comprenden dominios constantes quimericos.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
AU2018226215B2 (en) Immunoconjugates with optimized linkers and orientation
MX2023008912A (es) Constructos, composiciones y métodos de anticuerpos multiespecíficos multiafinidad.
EP4273161A4 (en) Protein with heterodimeric antibody FC and manufacturing method therefor
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
WO2019090215A3 (en) Dominant negative ligand chimeric antigen receptor systems